Top

Clinical Reviews in Allergy & Immunology

Published in:

01-04-2011

Scleroderma Lung Disease

Authors: Jérôme Le Pavec, David Launay, Stephen C. Mathai, Paul M. Hassoun, Marc Humbert

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2011

Abstract

Pulmonary involvement is second in frequency only to esophageal involvement as a visceral complication of systemic sclerosis (SSc) and has surpassed renal involvement as the most common cause of death. Interstitial lung disease and pulmonary vascular disease, particularly pulmonary arterial hypertension, are the most commonly encountered types of lung involvement. Chronic aspiration, airway disease, neuromuscular weakness, extrinsic pulmonary restrictive pathology, pleural effusions, pneumothorax, and lung cancer cause clinically significant disease and occur commonly enough to be routinely considered in the assessment of the SSc patient with respiratory symptoms. Affected patients have a significantly worse prognosis than patients with SSc who are free of pulmonary involvement.

Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37–50PubMed

Tan FK (2003) Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 29:211–237PubMed

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed

Silver RM (1996) Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 22:825–840PubMed

Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944PubMed

Diot E, Boissinot E, Asquier E, Guilmot JL, Lemarie E, Valat C, Diot P (1998) Relationship between abnormalities on high-resolution ct and pulmonary function in systemic sclerosis. Chest 114:1623–1629PubMed

Wells AU, Rubens MB, du Bois RM, Hansell DM (1993) Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol 161:1159–1165PubMed

Ostojic P, Damjanov N (2006) Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol 25:453–457PubMed

Toya SP, Tzelepis GE (2009) The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications. Rheumatol Int 29:861–868PubMed

10.

Morelli S, Barbieri C, Sgreccia A, Ferrante L, Pittoni V, Conti F, Gualdi G, Polettini E, Carlesimo OA, Calvieri S (1997) Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 24:81–85PubMed

11.

McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA et al (2007) Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 57:318–326PubMed

12.

Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE (1996) Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 90:223–230PubMed

13.

Alton E (1988) Turner-Warwick M. Lung involvement in scleroderma. Black, CM, Jayson MIV, Wiley, Chichester

14.

Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA (1998) African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 114:801–807PubMed

15.

Okano Y, Steen VD, Medsger TA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100PubMed

16.

Sacks DG, Okano Y, Steen VD, Curtiss E, Shapiro LS, Medsger TA Jr (1996) Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3rnp antibody. J Rheumatol 23:639–642PubMed

17.

Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35–42PubMed

18.

Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203PubMed

19.

Wallace DJ, Lin HC, Shen GQ, Peter JB (1994) Antibodies to histone (h2a–h2b)–DNA complexes in the absence of antibodies to double-stranded DNA or to (h2a–h2b) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum 37:1795–1797PubMed

20.

Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, Curran-Everett D, Gillis JZ, Meehan RT, Brown KK (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134:601–605PubMed

21.

Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, du Bois RM (1997) Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 40:1229–1236PubMed

22.

Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581–1586PubMed

23.

Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, Han J (2002) Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 22 Spec No:S151–S165

24.

Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, Delannoy V, Queyrel V, Duhamel A, Matran R et al (2006) High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 33:1789–1801PubMed

25.

Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF et al (2008) High-resolution ct scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 134:358–367PubMed

26.

Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177:1248–1254PubMed

27.

Fujita J, Yoshinouchi T, Ohtsuki Y, Tokuda M, Yang Y, Yamadori I, Bandoh S, Ishida T, Takahara J, Ueda R (2001) Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 60:281–283PubMed

28.

Nakamura Y, Chida K, Suda T, Hayakawa H, Iwata M, Imokawa S, Tsuchiya T, Ida M, Gemma H, Yasuda K et al (2003) Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 20:235–241PubMed

29.

Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, Hansell DM, Nicholson AG (2004) Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 44:585–596PubMed

30.

al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD, Medsger TA Jr (1989) Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 16:1038–1042PubMed

31.

Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM (1993) The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 148:1076–1082PubMed

32.

Muller NL, Miller RR (1990) Computed tomography of chronic diffuse infiltrative lung disease. Part 1. Am Rev Respir Dis 142:1206–1215PubMed

33.

Wells AU, Hansell DM, Rubens MB, Cullinan P, Haslam PL, Black CM, Du Bois RM (1994) Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings relation to computed tomographic appearance. Am J Respir Crit Care Med 150:462–468PubMed

34.

Harrison NK, Glanville AR, Strickland B, Haslam PL, Corrin B, Addis BJ, Lawrence R, Millar AB, Black CM, Turner-Warwick M (1989) Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mtc-dtpa clearance. Respir Med 83:403–414PubMed

35.

Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups (1990) The BAL cooperative group steering committee. Am Rev Respir Dis 141:S169–S202

36.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666PubMed

37.

Al-Dhaher FF, Pope JE, Ouimet JM (2008) Determinants of morbidity and mortality of systemic sclerosis in canada. Semin Arthritis Rheum

38.

Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413PubMed

39.

Highland KB, Silver RM (2005) New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 17:737–745PubMed

40.

Steen VD, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283–1289PubMed

41.

Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMed

42.

Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R et al (2008) Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 177:91–98PubMed

43.

Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729–735PubMed

44.

White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947–954PubMed

45.

Airo P, Danieli E, Parrinello G, Antonioli CM, Cavazzana I, Toniati P, Franceschini F, Cattaneo R (2004) Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 22:573–578PubMed

46.

Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371–2378PubMed

47.

Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298–304PubMed

48.

Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844PubMed

49.

Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr (1994) Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37:1290–1296PubMed

50.

Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, Cobankara V, Pay S, Calguneri M (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48:2256–2261PubMed

51.

Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455–461PubMed

52.

Martinez FJ, McCune WJ (2006) Cyclophosphamide for scleroderma lung disease. N Engl J Med 354:2707–2709PubMed

53.

Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026–1034PubMed

54.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970PubMed

55.

Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10:R124PubMed

56.

Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J et al (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35:1064–1072PubMed

57.

Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25:205–212PubMed

58.

Stratton RJ, Wilson H, Black CM (2001) Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40:84–88

59.

Liossis SN, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45:1005–1008

60.

Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130:30–36PubMed

61.

Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, Golden JA (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102:150–155PubMed

62.

Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455–460PubMed

63.

Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE, Larghero J, Gluckman E, Preijers FW, van Dijk AP et al (2008) Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67:98–104PubMed

64.

Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255–273PubMed

65.

Rosenbloom J, Jimenez SA (2008) Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum 58:2219–2224PubMed

66.

Rosas V, Conte JV, Yang SC, Gaine SP, Borja M, Wigley FM, White B, Orens JB (2000) Lung transplantation and systemic sclerosis. Ann Transplant 5:38–43PubMed

67.

Massad MG, Powell CR, Kpodonu J, Tshibaka C, Hanhan Z, Snow NJ, Geha AS (2005) Outcomes of lung transplantation in patients with scleroderma. World J Surg 29:1510–1515PubMed

68.

Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111–117PubMed

69.

Chang B, Wigley FM, White B, Wise RA (2003) Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 30:2398–2405PubMed

70.

MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM (2001) Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 40:453–459

71.

Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, Ito K (1997) Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest 111:36–43PubMed

72.

Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C (2005) The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the uncover study). Arthritis Rheum 52:2125–2132PubMed

73.

Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, Bookman A, Abu-Hakima M (2005) Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 32:1273–1278PubMed

74.

Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Frances C, Launay D et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52:3792–3800PubMed

75.

Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088–1093PubMed

76.

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F et al (2006) Pulmonary arterial hypertension in france: results from a national registry. Am J Respir Crit Care Med 173:1023–1030PubMed

77.

Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, Mouthon L, Hatron PY, Jego P, Allanore Y et al (2009) The 3-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France (itinérair-sclérodermie study). Arthritis Rheum 60:1831–1839PubMed

78.

Steen V, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516–522PubMed

79.

Steen V (2003) Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 62:97–99PubMed

80.

Chang B, Schachna L, White B, Wigley FM, Wise RA (2006) Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 33:269–274PubMed

81.

Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD, Ahern MJ, Roberts-Thomson PJ (2005) Isolated pulmonary hypertension in scleroderma. Intern Med J 35:28–33PubMed

82.

Hachulla E, Coghlan JG (2004) A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 63:1009–1014PubMed

83.

Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, Origgi L, Ponti A, Marchini M, Vanoli M (2002) Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 966:238–246PubMed

84.

Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE (2007) Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 36:392–396PubMed

85.

Ong YY, Nikoloutsopoulos T, Bond CP, Smith MD, Ahern MJ, Roberts-Thomson PJ (1998) Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 16:81–86PubMed

86.

Lee CY, Chang SM, Hsiao SH, Tseng JC, Lin SK, Liu CP (2007) Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion. Echocardiography 24:118–125PubMed

87.

Hsiao SH, Lee CY, Chang SM, Lin SK, Liu CP (2006) Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr 19:507–514PubMed

88.

Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, Guillevin L, Kahan A, Allanore Y (2008) Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 58:1803–1809PubMed

89.

Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, Denton CP, Black CM, Coghlan JG (2006) Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27:1485–1494PubMed

90.

Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92:926–932PubMed

91.

Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989–993PubMed

92.

Mayes MD (2003) Scleroderma epidemiology. Rheum Dis Clin North Am 29:239–254PubMed

93.

Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wigley F, Hassoun PM (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54:3043–3050PubMed

94.

Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM (2005) Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 24:1626–1631PubMed

95.

Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123:344–350PubMed

96.

Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM (2003) Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167:580–586PubMed

97.

Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179:151–157PubMed

98.

Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, Launay D, Mouthon L, Jego P, Cabane J et al (2009) Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French itinérair-sclérodermie study. Rheumatology (Oxford) 48:304–308

99.

Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti MC, Champion HC, Abraham TP et al (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174:1034–1041PubMed

100.

Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion HC, Girgis RE, Hassoun PM (2008) Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 177:1364–1369PubMed

101.

D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective study. Ann Intern Med 115:343–349PubMed

102.

Budhiraja R, Tuder RM, Hassoun PM (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109:159–165PubMed

103.

Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111PubMed

104.

Dorfmuller P, Perros F, Balabanian K, Humbert M (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358–363PubMed

105.

Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182–189PubMed

106.

Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, Simonneau G, Humbert M (2008) Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 58:521–531PubMed

107.

Vane JR, Anggard EE, Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27–36PubMed

108.

Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 334:296–302PubMed

109.

McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338:273–277PubMed

110.

Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485–491PubMed

111.

McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477–1482PubMed

112.

Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780–788PubMed

113.

Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434PubMed

114.

Farber HW, Graven KK, Kokolski G, Korn JH (1999) Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol 26:1195–1196PubMed

115.

Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF (1998) Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 113:237–240PubMed

116.

Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, Capron F (2007) Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38:893–902PubMed

117.

Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903PubMed

118.

Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123PubMed

119.

Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, Hatron PY, Beregi JP, Hachulla E (2008) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis

120.

Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65:1336–1340PubMed

121.

Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, Simonneau G (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417–2422PubMed

122.

Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521–530PubMed

123.

Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM (2007) Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 29:469–475PubMed

124.

Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC (2003) Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124:2098–2104PubMed

125.

Mathai SC, Hummers L, Champion HC, Wigley F, Zaiman A, Hassoun PM, Girgis R (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569–577PubMed

126.

Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A, Cotelingam J, Benjamin SB (1989) Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 149:589–593PubMed

127.

Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45:346–354PubMed

128.

Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Scholmerich J, Holstege A (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93:341–345PubMed

129.

Ing AJ (2001) Interstitial lung disease and gastroesophageal reflux. Am J Med 111(Suppl 8A):41S–44SPubMed

130.

Troshinsky MB, Kane GC, Varga J, Cater JR, Fish JE, Jimenez SA, Castell DO (1994) Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 121:6–10PubMed

131.

Daniels CE, Jett JR (2005) Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 11:431–437PubMed

132.

Hazleman B (1985) Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. Am J Med 78:39–43PubMed

133.

Hill CL, Nguyen AM, Roder D, Roberts-Thomson P (2003) Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62:728–731PubMed

134.

Rosenthal AK, McLaughlin JK, Linet MS, Persson I (1993) Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 52:531–533PubMed

135.

Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T (2001) Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21:106–111PubMed

136.

Roumm AD, Medsger TA Jr (1985) Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 28:1336–1340PubMed

137.

Chatterjee S, Dombi GW, Severson RK, Mayes MD (2005) Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52:2415–2424PubMed

138.

Highland KB, Garin MC, Brown KK (2007) The spectrum of scleroderma lung disease. Semin Respir Crit Care Med 28:418–429PubMed

139.

Clements PJ, Furst DE, Campion DS, Bohan A, Harris R, Levy J, Paulus HE (1978) Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 21:62–71PubMed

140.

Olsen NJ, King LE Jr, Park JH (1996) Muscle abnormalities in scleroderma. Rheum Dis Clin North Am 22:783–796PubMed

141.

Abramson MJ, Barnett AJ, Littlejohn GO, Smith MM, Hall S (1991) Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? Postgrad Med J 67:632–637PubMed

142.

Vitali C, Viegi G, Tassoni S, Tavoni A, Paoletti P, Bibolotti E, Ferri C, Bombardieri S (1986) Lung function abnormalities in different connective tissue diseases. Clin Rheumatol 5:181–188PubMed

143.

Blom-Bulow B, Jonson B, Brauer K (1985) Lung function in progressive systemic sclerosis is dominated by poorly compliant lungs and stiff airways. Eur J Respir Dis 66:1–8PubMed

144.

Owens GR, Fino GJ, Herbert DL, Steen VD, Medsger TA Jr, Pennock BE, Cottrell JJ, Rodnan GP, Rogers RM (1983) Pulmonary function in progressive systemic sclerosis. Comparison of crest syndrome variant with diffuse scleroderma. Chest 84:546–550PubMed

145.

Bjerke RD, Tashkin DP, Clements PJ, Chopra SK, Gong H Jr, Bein M (1979) Small airways in progressive systemic sclerosis (PSS). Am J Med 66:201–209PubMed

146.

Boehler A, Vogt P, Speich R, Weder W, Russi EW (1996) Bronchiolitis obliterans in a patient with localized scleroderma treated with d-penicillamine. Eur Respir J 9:1317–1319PubMed

147.

Thompson AE, Pope JE (1998) A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol 37:1320–1323PubMed

148.

Taormina VJ, Miller WT, Gefter WB, Epstein DM (1981) Progressive systemic sclerosis subgroups: variable pulmonary features. AJR Am J Roentgenol 137:277–285PubMed

149.

Zeuner M, Muller-Ladner U, Mohr VD, Lang B (1996) Spontaneous pneumothorax in a patient with systemic sclerosis. Clin Rheumatol 15:211–213PubMed

150.

Suresh K, Radha R, Ananthasubramaniam G, Chandrasekaran AN (1994) An unusual presentation of progressive systemic sclerosis. J Assoc Physicians India 42:163–164PubMed

151.

Ng SC, Tan WC (1990) Bilateral spontaneous pneumothorax in systemic sclerosis—report of two cases. J Rheumatol 17:689–691PubMed

152.

Lang B, Ortlieb H, Meske S, Hauke G, Peter HH (1989) Progressive systemic sclerosis presenting with spontaneous pneumothorax. J Rheumatol 16:254–256PubMed

Title: Scleroderma Lung Disease
Authors: Jérôme Le Pavec
David Launay
Stephen C. Mathai
Paul M. Hassoun
Marc Humbert
Publication date: 01-04-2011
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2011
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-009-8194-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis

Diagnosis and Classification of Systemic Sclerosis

The Pathogenesis of Systemic Sclerosis Revisited

Idiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review

A Contemporary Update on Scleroderma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials